DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2008/0139531 A1 Yanni Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2008/0139531 A1 Yanni Et Al US 2008O139531A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0139531 A1 Yanni et al. (43) Pub. Date: Jun. 12, 2008 (54) USE OF CONNECTIVE TISSUE MAST CELL Publication Classification STABILIZERS TO FACILITATE OCULAR SURFACE RE-EPTHELIZATION AND (51) Int. Cl. A6II 3/55 (2006.01) WOUND REPAIR A63L/335 (2006.01) (75) Inventors: John M. Yanni, Burleson, TX (US); A 6LX 3/59 (2006.01) Daniel A. Gamache, Arlington, TX A 6LX 3L/505 (2006.01) (US); Steven T. Miller, Arlington, A6II 3/4422 (2006.01) TX (US) (52) U.S. Cl. ................. 514/214.02: 514/450; 514/258.1; 514/256; 514/356 Correspondence Address: ALCON (57) ABSTRACT IP LEGAL, TB4-8, 6201 SOUTH FREEWAY Disclosed are methods of treating a wound in a subject that FORTWORTH, TX 76134 involve administering to the Subject a pharmaceutically effec tive amount of a composition that includes one or more (73) Assignee: ALCONMANUFACTURING human connective tissue mast cell stabilizers, wherein LTD., Fort Worth, TX (US) administration of the composition results in treatment of the wound. In particular embodiments, the wound is an oph (21) Appl. No.: 11/947,041 thalmic or dermal wound, Such as a corneal epithelial defect, a conjunctival wound, or dermal abrasion. Administration, (22) Filed: Nov. 29, 2007 for example, may be by topical application of the composition to the ocular surface or skin. Exemplary mast cell stabilizers Related U.S. Application Data include olopatadine, variants of olopatadine, alcaftidine, (60) Provisional application No. 60/872,715, filed on Dec. derivatives of alca?tidine, dihydropyridines, and spleen 4, 2006. tyrosine kinase inhibitors. US 2008/O 139531 A1 Jun. 12, 2008 USE OF CONNECTIVE TISSUE MAST CELL as in fibrotic skin disease (Nishikori et al., 1998). In particu STABILIZERS TO EACILITATE OCULAR lar, it has been reported that the healing process in an animal SURFACE RE-EPTHELIZATION AND model of wound healing corresponded strongly with mast cell WOUND REPAIR density and chymase activity in both acute and Subacute phases of wound healing. Recently, however, it has been shown that chymase released from activated mast cells may 0001. This application claims priority to U.S. Provisional inhibit the repair of Scratch-damaged monolayers of epithe Application, U.S. Ser. No. 60/872,715 filed Dec. 4, 2006. lial cells in vitro (Gordon, 2005). Thus, the precise role of mast cell chymase in corneal epithelial wound healing is BACKGROUND OF THE INVENTION unknown. 0002 1. Field of the Invention SUMMARY OF THE INVENTION 0003. The present invention relates generally to the field of 0011. The present invention overcomes drawbacks of the mast cell stabilizers, pharmaceutics, and the treatment and prior art by providing for novel methods of treating wounds in prevention of wounds. More particularly, the present inven a subject, such as ocular surface wounds and skin wounds. In particular, the inventors have found that inhibitors of mast cell tion concerns methods of treating or preventing a wound in a chymase release can be applied in the treatment of wounds in Subject that involve administering a pharmaceutically effec a subject. For example, topical olopatadine, a mast cell sta tive amount of a composition comprising one or more mast bilizer that inhibits mast cell chymase release, can aid in the cell stabilizers to the wound of the subject. process of corneal and/or conjunctival re-epithelialization 0004 2. Description of Related Art and wound repair. 0005 Wounds of the ocular surface, such as a corneal 0012. The invention set forth herein is generally directed epithelial defect, are exceedingly common and occur under to a method of treating a wound in a subject, involving admin many different circumstances. For example, a corneal epithe istering to the Subject a pharmaceutically effective amount of lial defect may be due to trauma, infection, a side effect of a composition that includes one or more mast cell Stabilizers, allergic conjunctivitis, contact lens wear, exposure keratopa wherein administration of the pharmaceutically effective thy, or ocular Surgery. Measures to promote healing are amount of the composition results in treatment of the wound. numerous, and include the discontinuation of potentially In a particular embodiment, the wound is an ophthalmic toxic medications and the use of ophthalmic lubricants, anti wound. In another embodiment, the wound is a skin wound. infective agents, and anti-inflammatory agents. Other mea 0013. A “subject” refers to either a human or non-human, Sures to promote healing include the protection of the ocular Such as primates, mammals, and Vertebrates. In particular Surface. Such as through the use of a patch, a bandage contact embodiments, the Subject is a human. lens and tarSorrhaphy. 0014. A “wound” is defined herein to refer to a break or 0006 Although many patients respond to conventional disruption in the continuity of cells of a tissue Surface of a subject. Any cause of disruption of the continuity of the cells therapies, there remains a significant Subset of patients who of a tissue surface of a subject is contemplated by this defi fail conventional therapies. Failure of the wound to heal can nition. For example, the disruption may be caused by Surgery be extremely frustrating for both patient and physician. or trauma. Other causes of wounds include infections and 0007 New therapies are under investigation, and include inflammation. The surface of the organ may be the surface of nerve growth factors, the use of fetal cord blood, the use of the eye. Such as the corneal Surface or the conjunctival Sur amniotic membrane, and the use of limbal stem cell grafting face. (reviewed in www.uveitis.org/medical/articles/clinical/ 00.15 Examples of cells that make up the tissue surface growth.html). It is not yet known whether any of these mea include epithelial cells and mucosal cells. The disruption of sures will result in effective treatment of an ocular surface the cells that may up the tissue surface may either involve the wound. Thus, there is the need for more effective treatments full-thickness of the cell layer or may be involve only a of ocular surface wounds. portion of the cell layer. For example, included in the defini 0008 Mast cells are a type of cell that is known to be tion of “wound is a corneal epithelial defect that is full involved in inflammatory responses. A wide variety of stimuli thickness (i.e., a defect to the basement membrane of the may cause the activation of mast cells, and Subsequently corneal), or a partial disruption of the corneal epithelial layer, cause them to migrate to a particular location and/or to and includes corneal abrasions and corneal ulcers. undergo de-granulation. These stimuli may be immunologic 0016. In a particular embodiment, the wound is a corneal (such as antibodies or allergens) or non-immunologic (Such wound. For example, the corneal wound may further be defined as a corneal epithelial defect, a recurrent corneal as chemical agents) in nature. erosion, or a corneal ulcer. Included within the definition of 0009. The precise role of mast cells in wound healing is corneal epithelial defect is punctate epithelial keratopathy. unknown. Understanding the role of mast cells, if any, in The corneal epithelial defect may be due to any cause or be wound healing is made difficult by the fact that mast cell types associated secondarily with any ophthalmic condition. For differ within species. Further, mast cell populations exist example, the corneal epithelial defect may be caused by within the same species which differ in phenotype, biochemi trauma (Surgical or nonSurgical), infection (e.g., bacterial, cal properties, functional responses, and pharmacological viral, or fungal keratitis), inflammation (e.g., secondary to responses. For example, one Subtype of mast cells, MC, is allergic conjunctivitis, giant papillary conjunctivitis, Vernal known to be present in the skin and conjunctiva, but not in conjunctivitis, atopic keratoconjunctivitis), chemical or ultra other tissues. violet exposure of the cornea, or dry eye syndrome. The 0010 Chymase, a serine protease found in MC, mast defect may also be associated with the use of preserved topi cells, is an important marker for human mast cells as well as cal products, keratitis, blepharitis, uveitis, tear film instabil a mediator of inflammation and matrix remodelling (Buckley ity, or be iatrogenic. In further particular embodiments, the et al., 1999). It has been suggested that skin mast cells and corneal epithelial defect is a persistent corneal epithelial mast cell chymase participates in the healing process as well defect that has been unresponsive to conventional therapy. US 2008/O 139531 A1 Jun. 12, 2008 0017. In another embodiment, the wound is a conjunctival methanol, 8-fluoro-6,11-dihydro-11-(1-methyl-4- wound. For example, the conjunctival wound may be a wound piperidinylidene)-5H-imidazo[2,1-b3RE 11-(1-methyl-4-piperidinylidene)-5H-imidazo[2.1- benzazepine, 6,11 associated with ophthalmic Surgery, trauma, or conjunctival b3 benzazepine-3-carboxaldehyde, 6,11-dihydro-11-(1- disease such as allergic conjunctivitis, giant papillary con methyl-4-piperidinylidene)-5H-imidazo[2,1-b3 junctivitis, Vernal conjunctivitis, or atopic keratoconjunctivi benzazepine-3 carboxylic acid, 7-fluoro-6,11-dihydro-11-(1- tis. methyl-4-piperidinylidene)-5H-imidazo[2,1-b3 benzazepine, 4-(8-fluoro-5,6-dihydro-11H-imidazo[2.1-b 0.018. In further embodiments, the wound is a skin wound. 3)benzazepin-11-ylidene)-1-piperidinepropanoic acid The skin wound may be the result of trauma (Surgical or dihydrate, methyl cis-11-(3-dimethylaminopropylidene)-6, nonsurgical), infection, inflammation, burn, or primary skin 11-dihydrodibenz beloxepin-2-carboxylate, methyl trans disease. Examples of primary skin diseases include blistering 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenzbe oxepin-2-carboxylate.
Load more

Recommended publications
  • Allergies Your Amerigroup Community Care Patients May Experience a Pharmacy Claim Rejection When Prescribed Nonpreferred Products
    Provider update Hot Tip: Allergies Your Amerigroup Community Care patients may experience a pharmacy claim rejection when prescribed nonpreferred products. To avoid additional steps or delays at the pharmacy, consider prescribing preferred products whenever possible. Utilization Management edits may apply to select preferred products. Coverage should be verified by reviewing the Preferred Drug List (PDL) on the Amerigroup provider website. The PDL is subject to change quarterly. Therapeutic class Preferred products Nonpreferred products Oral • Fexofenadine (generic Allegra) • Cetirizine (generic Zyrtec) antihistamines1 • Fexofenadine/ pseudoephedrine • Cetirizine/pseudoephedrine (generic Allegra-D) (generic Zyrtec D) • Loratadine (generic Claritin) • Zyrtec (cetirizine) • Loratadine/pseudoepherine • Zyrtec D (cetirizine/ (generic Claritin D) pseudoephedrine) • Clarinex (desloratadine) • Desloratadine (generic Clarinex) • Alegra (fexofenadine) • Allegra D (fexofenadine/ pseudoephedrine) • Levocetirizine (generic Xyzal) • Xyzal (levocetirizine) • Claritin (loratadine) • Claritin D (loratadine/ pseudoephedrine) Nasal steroids2 • OTC budesonide nasal spray • Flonase Sensimist (fluticasone (generic Rhinocort) furoate) • OTC Rhinocort Allergy • Flonase (fluticasone propionate) (budesonide) • Rx fluticasone propionate (generic • OTC fluticasone propionate Rx Flonase) (generic Flonase) • Mometasone furoate (generic • OTC triamcinolone acetonide Nasonex) (generic Nasacort) • Nasacort (triamcinolone acetonide) • Nasonex (mometasone furoate) • Omnaris
    [Show full text]
  • Medication Instructions for Allergy Patients
    MEDICATION INSTRUCTIONS FOR ALLERGY PATIENTS Drugs which contain antihistamine or have antihistaminic effects can result in negative reactions to skin testing. As a result, it may not be possible to properly interpret skin test results, and testing may have to be repeated at a later date. While this list is extensive, it is NOT all inclusive (particularly of the various brand names). Discontinue ALL antihistamines including the following medications seven (7) days prior to skin testing (unless longer time specified): Antihistamines – Generic name (Brand name(s)): Cetirizine (Zyrtec, Zyrtec-D) Hydroxyzine (Vistaril, Atarax) Desloratadine (Clarinex) Levocetirizine (Xyzal) Fexofenadine (Allegra, Allegra-D) Loratadine (Claritin, Claritin-D, Alavert) Diphenhydramine (Aleve PM, Benadryl, Bayer P.M., Benylin, Contac P.M., Doans P.M, Excedrin PM, Legatrin P.M.. Nytol, Tylenol Nighttime, Unisom, Zzzquil) Chlorpheniramine (Aller-Chlor, Allerest, Alka Seltzer Plus, Chlor-Trimeton, Comtrex, Contac, Co-Pyronil, Coricidin, CTM, Deconamine, Dristan, Dura-tap, Naldecon, Ornade Spansules, Rondec, Sinutab, Teldrin, Triaminic, Triaminicin, Tylenol Allergy) Azatadine (Optimine, Trinalin) Doxylamine (Nyquil) Brompheniramine (Bromfed, Dimetane, Dimetapp) Meclizine (Antivert) Carbinoxamine (Clistin, Rondec) Pheniramine Clemastine (Tavist) Phenyltoloxamine (Nadecon) Cyclizine (Marezine) Promethazine (Phenergan) Cyprohepatidine (Periactin) (9 days) Pyrilamine (Mepyramine) Dexbrompheniramine (Drixoral) Quinacrine (Atabrine) Dexchlorpheniramine (Extendryl, Polaramine)
    [Show full text]
  • 22134 Alcaftadine Clinical PREA
    Clinical Review Martin P Nevitt M.D., M.P.H NDA 22-134 (b) (4) (alcaftadine ophthalmic solution) 0.25% CLINICAL REVIEW Application Type NDA Application Number(s) 22-134 Priority or Standard S Submit Date(s) September 29, 2009 Received Date(s) September 29, 2009 PDUFA Goal Date July 28, 2010 Division / Office DAIOP Reviewer Name(s) Martin P. Nevitt, M.D.,M.P.H. Review Completion Date April 2, 2010 Established Name alcaftadine ophthalmic solution, 0.25% (Proposed) Trade Name Lastacaft Therapeutic Class histamine H1 receptor antagonist Applicant Vistakon Pharmaceuticals, LLC Formulation(s) Topical ophthalmic Dosing Regimen One drop each eye daily Indication(s) Prevention of itching associated with allergic conjunctivitis Intended Population(s) Patients ≥ 2 years old 1 Clinical Review Martin P Nevitt M.D., M.P.H NDA 22-134 (b) (4) (alcaftadine ophthalmic solution) 0.25% Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT......................................... 5 1.1 Recommendation on Regulatory Action ............................................................. 5 1.2 Risk Benefit Assessment.................................................................................... 5 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ... 5 1.4 Recommendations for Postmarket Requirements and Commitments ................ 5 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 5 2.1 Product Information ...........................................................................................
    [Show full text]
  • Medications That May Interfere with Skin Testing
    MEDICATIONS THAT MAY INTERFERE WITH SKIN TESTING • Due to continued advances, not all medications may be listed at time of printing. • For your safety and accurate results, at each visit, please list all your current medications (including non-prescription and those prescribed elsewhere). • It is important to let us know if you are pregnant or could be pregnant. STOP THESE MEDICATIONS FIVE DAYS BEFORE SKIN TESTING: ORAL ANTIHISTAMINES: ANTIHISTAMINE NOSE SPRAYS: • Allegra (Fexofenadine) • Astelin, Astepro, Dymista (Azelastine) • Benadryl (Diphenhydramine) • Patanase (Olopatadine) • Claritin, Alavert (Loratadine) • Clarinex (Desloratadine) ANTIHISTAMINE EYE DROPS: • Xyzal (Levocetirizine) • Alaway, Claritin, Zaditor, Zyrtec (Ketotifen) • Zyrtec (Cetirizine) • Bepreve (Bepotastine) • Cyproheptadine • Elestat (Epinastine) · All over-the-counter medications for allergy, cough, cold, sleep, • Emadine (Emedastine) or nausea that include: • Lastacaft (Alcaftadine) oAcrivastine (ex. Semprex) • Livostin (Levocabastine) oAzatadine (ex. Optimine, Trinalin) • Naphcon-A, Opcon-A, Visine-A oBrompheniramine (ex. Dimetapp) (Pheniramine) oCarbinoxamine (ex. Palgic, Arbinoxa) • Optivar (Azelastine) oChlorpheniramine (ex. Actifed, Aller-chlor, Chlor- • Pataday, Patanol (Olopatadine) Trimeton, Tylenol Allergy) oDimenhydrinate (ex. Dramamine) HEARTBURN MEDICATIONS (H2 BLOCKERS): oDiphenhydramine (ex. Unisom, Sominex, • Axid (Nizatidine) Triaminic, many with “PM” in the title) • Pepcid, Tums Dual Action (Famotidine) oDoxylamine (ex. Nyquil, Unisom) • Tagament
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Cross-Discipline Team Leader Review for NDA 22-134 1
    Cross-Discipline Team Leader Review for NDA 22-134 Date June 22, 2010 From William M. Boyd, M.D. Subject Cross-Discipline Team Leader Review NDA # 22-134 Applicant Vistakon Pharmaceuticals, LLC Date of Submission September 29, 2009 PDUFA Goal Date July 29, 2010 Type of Application 505(b)(1) Name Lastacaft (alcaftadine ophthalmic solution) 0.25% Dosage forms / Strength Topical ophthalmic solution Proposed Indication(s) Indicated for the prevention of itching associated with allergic conjunctivitis Recommended: Recommended for Approval 1. Introduction H3C N NN O H Chemical Name: 6,11-dihydro-11-(1-methyl-4-piperidinylidene)-5H-imidazo[2,1-b] [3] benzazepine-3-carboxaldehyde Lastacaft (alcaftadine ophthalmic solution) 0.25% is a H1 histamine antagonist and inhibitor of the release of histamine from mast cells. There is no previous marketing experience with Lastacaft (alcaftadine ophthalmic solution) 0.25% as the proposed active ingredient has not been previously approved in the United States or abroad. Throughout this review, alcaftadine ophthalmic solution 0.25% may alternately be referred to as Lastacaft, (b) (4) or R89674. 2. Background The efficacy endpoints chosen for the phase 3 studies have been widely used in clinical studies of ophthalmic solutions and are recognized as reliable, accurate, and relevant for evaluation of the efficacy and safety of investigational products. For an indication for the treatment of allergic conjunctivitis, a demonstration of efficacy is recommeded to include evidence of statistical CDTL Review William M. Boyd, M.D. NDA 22-134 Lastacaft (alcaftadine ophthalmic solution) 0.25% significance and clinical relevance in the resolution of both ocular itching and redness.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Medication Instructions for Allergy Patients
    MEDICATION INSTRUCTIONS FOR ALLERGY PATIENTS Drugs which contain antihistamine or have antihistaminic effects can result in negative reactions to skin testing. As a result, it may not be possible to properly interpret skin test results, and testing may have to be repeated at a later date. While this list is extensive, it is NOT all inclusive (particularly of the various brand names). Discontinue ALL antihistamines including the following medications seven (7) days prior to skin testing (unless longer time specified): Antihistamines – Generic name (Brand name(s)): Cetirizine (Zyrtec, Zyrtec-D) Hydroxyzine (Vistaril, Atarax) Desloratidine (Clarinex) Levocetirizine (Xyzal) Fexofenadine (Allegra, Allegra-D) Loratidine (Claritin, Claritin-D, Alavert) Diphenhydramine (Aleve PM, Benadryl, Bayer P.M., Benylin, Contac P.M., Doans P.M, Excedrin PM, Legatrin P.M.. Nytol, Tylenol Nighttime, Unisom, Zzzquil) Chlorpheniramine (Aller-Chlor, Allerest, Alka Seltzer Plus, Chlor-Trimeton, Comtrex, Contac, Co-Pyronil, Coricidin, CTM, Deconamine, Dristan, Dura-tap, Naldecon, Ornade Spansules, Rondec, Sinutab, Teldrin, Triaminic, Triaminicin, Tylenol Allergy) Azatadine (Optimine, Trinalin) Doxylamine (Nyquil) Brompheniramine (Bromfed, Dimetane, Dimetapp) Meclizine (Antivert) Carbinoxamine (Clistin, Rondec) Pheniramine Clemastine (Tavist) Phenyltoloxamine (Nadecon) Cyclizine (Marezine) Promethazine (Phenergan) Cyprohepatidine (Periactin) (9 days) Pyrilamine (Mepyramine) Dexbrompheniramine (Drixoral) Quinacrine (Atabrine) Dexchlorpheniramine (Extendryl, Polaramine)
    [Show full text]
  • Rx Hot Tip Allergies
    Empire BlueCross BlueShield HealthPlus (Empire) Hot Tip: Allergies Your Empire patients on nonpreferred products may experience a pharmacy claim rejection. To avoid additional steps or delays at the pharmacy, consider prescribing preferred products whenever possible. Prior authorization and step therapy may apply to select preferred products. Coverage should be verified by reviewing the Preferred Drug List (PDL) on the Empire provider website. The PDL is subject to change quarterly. Therapeutic Nonpreferred products Preferred products class Cetirizine (generic Zyrtec) Fexofenadine (generic Allegra) Cetirizine/pseudoephedrine (generic Fexofenadine/ pseudoephedrine Zyrtec D) (generic Allegra-D) Zyrtec (cetirizine) Loratadine (generic Claritin) Zyrtec D (cetirizine/ Loratadine/pseudoepherine pseudoephedrine) (generic Claritin D) Clarinex (desloratadine) Oral Desloratadine (generic Clarinex) Antihistamines1 Alegra (fexofenadine) Allegra D (fexofenadine/ pseudoephedrine) Levocetirizine (generic Xyzal) Xyzal (levocetirizine) Claritin (loratadine) Claritin D (loratadine/ pseudoephedrine) Flonase Sensimist (fluticasone OTC budesonide nasal spray furoate) (generic Rhinocort) Flonase (fluticasone propionate) OTC Rhinocort Allergy Rx fluticasone propionate (generic (budesonide) Rx Flonase) OTC fluticasone propionate Mometasone furoate (generic (generic Flonase) Nasonex) OTC triamcinolone acetonide Nasacort (triamcinolone acetonide) (generic Nasacort) Nasal Steroids2 Nasonex (mometasone furoate) Omnaris nasal spray (ciclesonide)
    [Show full text]
  • A Review of Fexofenadine Hydrochloride Farya Zafar* Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan
    Farya Zafar / Journal of Pharmacy Research 2012,5(3),1646-1649 Review Article Available online through ISSN: 0974-6943 http://jprsolutions.info A review of Fexofenadine hydrochloride Farya Zafar* Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan. Received on:10-12-2011; Revised on: 15-01-2012; Accepted on:12-02-2012 ABSTRACT Fexofenadine is the hydrochloride salt of terfenadine’s active metabolite. In 2006, the FDA approved an oral suspension for the management of chronic idiopathic urticaria and seasonal allergic rhinitis in children. This review article summarizes the clinical pharmacology, therapeutic applications, drug-drug interactions, adverse events and food-drug interactions of fexofenadine that have been reported in pervious years. Key words: Fexofenadine hydrochloride, chronic idiopathic urticaria, clinical pharmacology, therapeutic applications. INTRODUCTION More than 45 H1-antihistamines are accessible worldwide, including the various symptoms such as sneezing, rhinorrhea, nasal pruritus and watery major class of drugs used in the management of allergic disorders [1-5]. eyes [15] associated with allergic rhinitis [16-18]. Authors reported that antihis- Fexofenadine, is a histamine H 1- receptor antagonist having chemical name tamines (second generation) particularly, fexofenadine have anti-inflamma- (+)-4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]- [19, 15] tory response that may decrease nasal congestion . H1 receptor antago- a,a-dimethylbenzeneaceticacid hydrochloride. The empirical formula and nists usually have slight effect on this indication [20-22]. Antihistamine can be [23- the molecular weight is C32H39NO4.HCl and 538.13, respectively. combined with pseudoephedrine, to give complete symptomatic relief Fexofenadine hydrochloride is a racemate and exists as zwitterions in aque- 25].
    [Show full text]
  • ALLERGY - ANTIHISTAMINE & IMMUNOTHERAPY MEDICATION (Updated 07/28/2021)
    ALLERGY - ANTIHISTAMINE & IMMUNOTHERAPY MEDICATION (Updated 07/28/2021) I. CODE OF FEDERAL REGULATIONS First-Class Airman Medical Certificate: 67.105(b) & (c); 67.113(c) Second-Class Airman Medical Certificate: 67.205(b) & (c); 67.213(c) Third-Class Airman Medical Certificate: 67.305(b) & (c); 67.313(c) II. MEDICAL HISTORY: Item 18.e. Hay fever or allergy The applicant must report frequency and duration of symptoms, any incapacitation by the condition, treatment, and side effects. The Examiner must inquire whether the applicant has ever experienced any barotitis (‘ear block’), barosinusitis (‘sinus block’), alternobaric vertigo (‘dizziness’), difficulty breathing, rashes, or any other localized or systemic symptoms that could interfere with aviation safety. III. AEROMEDICAL DECISION CONSIDERATIONS: See Item 26. Nose See Item 35. Lungs and Chest IV. PROTOCOL: See Disease Protocols – Allergies, Severe V. PHARMACEUTICAL CONSIDERATIONS: Airmen who are exhibiting symptoms, regardless of the treatment used, must not fly. AME must warn that flight/safety-related duties are prohibited until after any applicable post-dose observation time. In all situations, the examiner must notate the evaluation data in Block 60. Medication: • New medications: o Symptoms must be controlled without adverse side effects. o Post-dose observation time: Mandatory 48-hour ground trial required after initial use. • Acceptable medications: o Do not instill antihistamine eye drops immediately before or during flight/safety related duties, as it is common to develop temporary blurred vision each time the drops are applied. o Post-dose observation time: Not required for acceptable medications (see chart below). • Conditionally acceptable medications: o May be used occasionally (1-2 times a week) with the stipulation that the airman not exercise the privileges of airman certificate while taking the medication.
    [Show full text]